Race Disparities in Proton Radiotherapy Use for Cancer Treatment in Patients Enrolled in Children’s Oncology Group Trials

Danielle S. Bitterman(Brigham and Women's Hospital), Daphne A. Haas‐Kogan(Brigham and Women's Hospital), Wendy B. London(Dana-Farber Cancer Institute), Pei-Chi Kao(Dana-Farber Cancer Institute), Fran Laurie, Kira Bona(Dana-Farber Cancer Institute), Stephanie Terezakis(University of Minnesota)
JAMA Oncology
August 6, 2020
10.1001/jamaoncol.2020.2259
Cited by 36

Related Papers

Molecular Determinants of the Response of Glioblastomas to EGFR Kinase Inhibitors
|New England Journal of Medicine|2005|1.4k
Artificial intelligence in radiation oncology
|Nature Reviews Clinical Oncology|2020|399
Pediatric high-grade glioma: biologically and clinically in need of new thinking
|Neuro-Oncology|2016|365
Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia
|JAMA|2021|358
The TRIPOD-LLM reporting guideline for studies using large language models
|Nature Medicine|2025|340